Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190BCR-ABL oncoprotein and JAK2V617F mutation

被引：12

作者：

Caocci, G. ^{[1
]}

Atzeni, S. ^{[1
]}

Orru, N. ^{[1
]}

Littera, R. ^{[1
]}

Culurgioni, F. ^{[2
]}

Marongiu, F. ^{[3
]}

La Nasa, G. ^{[1
]}

机构：

[1] Univ Cagliari, Cattedra Ematol, Dipartimento Sci Med Internist, Cagliari, Italy

[2] Osped Armando Businco, Unita Operat Ematol, Cagliari, Italy

[3] Univ Cagliari, Cattedra Med Interna, Dipartimento Sci Med Internist, Cagliari, Italy

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 01期

关键词：

DISEASE; MECHANISMS;

D O I：

10.1016/j.leukres.2009.08.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E27 / E29

页数：3

共 11 条

[1] Mechanisms of disease: The myeloproliferative disorders [J].

Campbell, Peter J. ;

Green, Anthony R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2452-2466

[2] Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment [J].

Goldman, JM ;

Melo, JV .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1451-1464

[3]

HUR M, 2001, LAB HEMATOL, V7, P65

[4] Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation [J].

Hussein, Kais ;

Bock, Oliver ;

Seegers, Anna ;

Flasshove, Michael ;

Henneke, Felicitas ;

Buesche, Guntram ;

Kreipe, Hans Heinrich .

BLOOD, 2007, 109 (09) :4106-4107

[5]

MELO JV, 1994, LEUKEMIA, V8, P208

[6] Philadelphia chromosome-positive chronic myeloid leukemia expressing p190BCR-ABL [J].

Ohsaka, A ;

Shiina, S ;

Kobayashi, M ;

Kudo, H ;

Kawaguchi, R .

INTERNAL MEDICINE, 2002, 41 (12) :1183-1187

[7] A case of coexistence between JAK2V617F and BCR/ABL [J].

Pardini, Simonetta ;

Fozza, Claudio ;

Contini, Salvatore ;

Rimini, Elena ;

Ottaviani, Emanuela ;

Amabile, Marilina ;

Rosti, Gianantonio ;

Longinotti, Maurizio .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (01) :75-76

[8] The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes [J].

Steensma, DP ;

Dewald, GW ;

Lasho, TL ;

Powell, HL ;

McClure, RF ;

Levine, RL ;

Gilliland, DG ;

Tefferi, A .

BLOOD, 2005, 106 (04) :1207-1209

[9]

TEFFERI A, 2006, CLASSIFICATION DIAGN, P240

[10] Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis [J].

Traverse-Glehen, A. ;

Verney, A. ;

Baseggio, L. ;

Felman, P. ;

Callet-Bauchu, E. ;

Thieblemont, C. ;

Ffrench, M. ;

Magaud, J-P ;

Coiffier, B. ;

Berger, F. ;

Salles, G. .

LEUKEMIA, 2007, 21 (08) :1824-1826

← 1 2 →